Targeted degradation of CDK9 potently disrupts the MYC-regulated network
Mohammed A. Toure(Massachusetts Institute of Technology), Angela N. Koehler(Massachusetts Institute of Technology), Eliezer Calo(Massachusetts Institute of Technology), Florian Kabinger(Tissue Dynamics (Israel)), Stuart S. Levine(Massachusetts Institute of Technology), Charles A. Whittaker(Imperial College London), Samuel Ojeda(Massachusetts General Hospital), Kaitlyn Gagnon(Massachusetts General Hospital), Richard P. Schiavoni(Massachusetts Institute of Technology), André Richters(Massachusetts Institute of Technology), Jennifer A. Roth(Broad Institute), Yichen Xiang(Massachusetts Institute of Technology), Julie Urgiles(Broad Institute), Matthew G. Rees(Broad Institute), Keisuke Motoyama(Massachusetts Institute of Technology), Amruth Kumar(Massachusetts General Hospital), Drew A. Harrison(Massachusetts General Hospital), Ramya S. Iyer(Massachusetts General Hospital), Forest M. White(Center for Cancer Research), Christopher J. Ott(Broad Institute), Ann-Sophie Koglin(Massachusetts General Hospital)
Cited by 12
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
|Nature Biotechnology|2002|1.6k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling
|Nature Cancer|2020|880